BeStock  
Stocks › Biotechnology › ZVRA

Zevra Therapeutics ZVRA

US equityMarket cap rank #3557Biotechnology
$11.08 +$0.35 (+3.26%)
Pre-market · Oct 8, 7:00 am ET · After hours $11.19 +0.99%
Open$10.68
Prev close$10.73
Day range$10.57 – $11.38
Volume936.5K
Market cap$657.97M
P/E (TTM)11.9
Dividend yield–

Valuation

Multiples measured against the stock's own five-year history

Price / earnings11.9x
CheapRich

Near the top of its 5-year range · 85th percentile, 5-year average -2.3x

#810 of 2973 stocks by PE (1 = cheapest)

Price / book3.0x
CheapRich

Around its usual level · 45th percentile, 5-year average 4.4x

#3682 of 5317 stocks by PB (1 = cheapest)

Price / sales4.8x
CheapRich

Near the bottom of its 5-year range · 1st percentile, 5-year average 12.0x

#3825 of 5146 stocks by PS (1 = cheapest)

P/E over five years

-51x-25x0x26xOct '21Apr '24Oct '26

Dashed line is the 5-year average; the shaded band is one standard deviation either side.

Morningstar fair value estimate

Fair value$11.02
Price vs. fair value+0.6%Close to the estimate
Star rating★★★☆☆
Economic moatNone
UncertaintyMedium
MultipleCurrentForward5y averagePercentile vs. own historyIndustry rank
PB 3.02 – 4.38 45% (cheaper than usual) #3682 of 5317 (1 = cheapest)
PE 11.91 12.33 -2.28 85% (pricier than usual) #810 of 2973 (1 = cheapest)
PS 4.84 3.99 12.04 1% (cheaper than usual) #3825 of 5146 (1 = cheapest)

Percentile is against this stock’s own 5-year valuation range: higher means it’s trading rich relative to its own history, lower means cheap relative to its own history — it is not a comparison against other companies. Forward multiples use consensus estimates for the next twelve months; a forward multiple below the current one usually signals analysts expect earnings to grow.

Morningstar view

Star rating★★★
Fair value estimate$11.02
Economic moatNone
UncertaintyMedium

Discussion

No comments yet — be the first to weigh in on ZVRA.

Leave a comment

Scroll to Top